Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Amy Schmotzer"'
Autor:
Amit D. Tevar, Puneet Sood, Vikrant Rachakonda, H. Chen, Amy Schmotzer, Michael A. Dunn, Christopher B Hughes, Abhinav Humar, Deborah A. Josbeno, S.S. Kulkarni
Publikováno v:
Transplantation Proceedings. 51:794-797
Introduction Frailty measures can predict perioperative surgical risk in liver transplant patients. The 5-meter walk test (5MWT) and hand grip strength (HGS) are easy and reproducible frailty measures. We hypothesized that they could capture frailty
Autor:
Vikrant Rachakonda, Elizabeth A. Kallenborn, Andrea DiMartini, Douglas Landsittel, Amit D. Tevar, Swaytha Ganesh, Amy Schmotzer, Michael A. Dunn, Deborah A. Josbeno, Jaideep Behari, Anthony Delitto
Publikováno v:
The American journal of gastroenterology. 111(12)
Frailty is a known risk factor for major life-threatening liver transplant complications, deaths, and waitlist attrition. Whether frailty indicates risk for adverse outcomes in cirrhosis short of lethality is not well defined. We hypothesized that cl
Autor:
Douglas Landsittel, Andrea DiMartini, Anthony Delitto, Amy Schmotzer, Michael A. Dunn, Amit D. Tevar, Deborah A. Josbeno
Publikováno v:
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 22(10)
Frailty with sarcopenia in cirrhosis causes liver transplant wait-list attrition and deaths. Regular physical activity is needed to protect patients with cirrhosis from frailty. We subjectively assess physical performance in selecting patients for tr
Autor:
Joanna M. Brell, Ramesh K. Ramanathan, James J. Schlesselman, Terry Evans, Linda Rath, S. Dranko, Amy Schmotzer, Khalid Matin, Robert Volkin, Gauri J. Kiefer, Diana Lenzner
Publikováno v:
Oncology. 76:270-274
Background: There is no standard second-line therapy for advanced pancreatic cancer (APC). We evaluated the epidermal growth factor receptor (EGFR) inhibitor gefitinib and docetaxel in a phase II study following gemcitabine failure. Methods: EGFR ove
Autor:
Marwan Fakih, Nathan Bahary, Amy Schmotzer, Ramesh K. Ramanathan, Theodore L. Crandall, Ronald G. Stoller, Stewart L. Lancaster, R. A. Pinkerton, Douglas M. Potter, Barry C. Lembersky, Benedito A. Carneiro, Smitha S. Krishnamurthi
Publikováno v:
Clinical colorectal cancer. 11(1)
Background Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC. Patients and Methods Patients with
Autor:
Michelle Shayne, Shelly S. Lo, K. K. Rajasenan, Ramesh K. Ramanathan, Alexander Hantel, Sheryl Simon, Amy Schmotzer, Alok A. Khorana, Hong Wang, Jimmy J. Hwang, Milind Javle, Gauri J. Kiefer
Publikováno v:
Oncology. 78(2)
Objective: Docetaxel and capecitabine are active agents in advanced gastric and gastroesophageal (GE) carcinomas. This multi-institutional phase II trial evaluates the combination of docetaxel and capecitabine as first- or second-line treatment in pa
Autor:
Ronald G. Stoller, Douglas M. Potter, William C. Zamboni, Hitendra Patel, Amy Schmotzer, Miklos L Auber, Gauri J. Kiefer, Khalid Matin, Chao Cai, Ramesh K. Ramanathan
Publikováno v:
Investigational new drugs. 24(4)
Background: Rubitecan (RFS-2000, 9NC, Orathecin™ is an orally bioavailable camptothecin analogue, with evidence of preclinical activity in colon cancer cell lines. We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedu
Publikováno v:
Gastroenterology. 146:S-965
Autor:
Marwan Fakih, R. A. Pinkerton, Barry C. Lembersky, Ramesh K. Ramanathan, Nathan Bahary, S. Lancaster, Amy Schmotzer, Theodore L. Crandall, Alok A. Khorana, Smitha S. Krishnamurthi
Publikováno v:
Journal of Clinical Oncology. 26:15050-15050
15050 Background: I + C is a standard second line regimen for pts treated with 5-flurouracil, oxaliplatin and bevacizumab in the US. Second line therapy with I + C results in a response rate (RR) o...
Autor:
S. Dranko, Douglas M. Potter, Barry C. Lembersky, Edward P. Balaban, K. K. Rajasenan, Theodore L. Crandall, Ramesh K. Ramanathan, Amy Schmotzer, P. Kane, R. A. Pinkerton
Publikováno v:
Journal of Clinical Oncology. 25:4092-4092
4092 Background: FOLFOX in combination with Bev is a standard regimen for treating advanced CRC. Cap on a d 1–14 schedule every 3 weeks is now being substituted for 5-flurouracil (CapOx); however optimal doses and schedules of Cap in combination wi